Nov 16 (Reuters) – Incyte said on Monday the European Commission had approved its once-daily oral therapy for a type of chronic skin disease. The drug, Povofortay, chemically known as povorcitinib, was approved for adults with moderate-to-severe hidradenitis suppurativa who have responded inadequately to, or cannot take, anti-tumor necrosis factor therapies. Hidradenitis suppurativa is a […]
Health
Incyte says EU approves oral treatment for chronic skin disease
Audio By Carbonatix
Nov 16 (Reuters) – Incyte said on Monday the European Commission had approved its once-daily oral therapy for a type of chronic skin disease.
The drug, Povofortay, chemically known as povorcitinib, was approved for adults with moderate-to-severe hidradenitis suppurativa who have responded inadequately to, or cannot take, anti-tumor necrosis factor therapies.
Hidradenitis suppurativa is a chronic inflammatory skin condition characterized by painful nodules, abscesses and scarring that can significantly affect patients’ quality of life.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Shinjini Ganguli)
